Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity

Published:2013-02-02 Issue:6 Volume:58 Page:1766-1775
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Fontana Robert J.,Hayashi Paul,Bonkovsky Herbert L.,Kleiner David E.,Kochhar Sweta,Gu Jiezhun,Ghabril Marwan

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-012-2553-1.pdf

Reference39 articles.

1. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129.

2. Weiner HL. Multiple sclerosis is an inflammatory T-cell mediated autoimmune disease. Arch Neurol. 2004;61:1613.

3. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized controlled trial. Neurology. 2003;60:44.

4. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63:1779.

5. Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26:815–827.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19;Safety and Risk of Pharmacotherapy;2024-05-02

2. Hepatotoxicity case due to interferon beta-1a use;Akademik Gastroenteroloji Dergisi;2023-12-22

3. Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility;International Journal of Molecular Sciences;2023-01-03

4. Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial;International Immunopharmacology;2021-08

5. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review;CNS Drugs;2021-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3